Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers
Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers
Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.